PerpEquities

Equity · Healthcare

IDEXX Laboratories, Inc. (IDXX) perpetual futures

IDXX perpetual futures on 1 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade IDXXUSDT.

IDEXX Laboratories provides diagnostic instruments, consumables, rapid tests, reference laboratory services and software to veterinary practices, livestock and dairy producers, water quality testers and biomedical researchers.

$708.71+3.9%NASDAQ closed
Open in terminal

Price chart

 

Use the left and right arrow keys to inspect points on the chart.

Collecting venue price data...
venue perp mark · MEXC (IDXX/USDT)
Auto: highest-volume live perp venueOpen in TradingView

Trading data

Perpetual market activity

1/1 live markets
Venues
1
Live markets
1/1
24h volume
$2.9K
Open interest
$5K
Best liquidity
$9.8K
MEXC
Tightest spread
+155.5 bps
MEXC
Highest volume
$2.9K
MEXC
Settlement mix
USDT · 1/1
Perp/spot vol.
0.00x
Spot volume $991.4M
OI / float
0.00%
Float $55.6B
Spot performance
1D+3.94%
5D+19.67%
1M+32.53%
6M+24.08%
YTD+3.25%
1Y-3.01%

Venue matrix

1 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
MEXCTradeIDXX/USDTTrading$708.71+15.4% APR
+0.014% every 8h
+155.5 bps$9.8K$2.9K$5KUSDT20x

Tradability

Execution quality

Entry cost and depth per venue at $1k–$100k

No sufficient depth · 0 of 1 venues absorb $10k

No fresh book data: MEXC

Taker execution estimate incl. approx. fees - maker fills are not guaranteed.

Best venues for this underlying

Best liquidity

IDXX

Tightest spread

IDXX

Highest volume

IDXX

Funding history

Stored venue snapshots by market

Company financials

Financials at a glance

Last report Q3 '26 · filed 2026-11-02 · next report 2027-02-01 · Updated 51m ago
All financials →

Valuation & key figures

Market cap
$55B
Updated 51m ago
Revenue
$4.7B
Trailing 12 months
Revenue growth
+10%
Next fiscal year
Profit margin
+25.4%
P/E
47.1
Peer P/E 28.9
P/S
11.8
Peer P/E
28.9
Similar listed perps
Free cash flow
$1.3B
Trailing 12 months
Net income
$1.2B
Trailing 12 months
Revenue estimate
$4.7B
Next fiscal year
Earnings
2027-02-01
Revenue est. $1.2B · Updated 51m ago
Dividend
-
Revenue (TTM)$4.66B+11.9% vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)32.3%+1.0 pp vs a year agoOperating income $1.51B
Net income (TTM)$1.18B+15.1% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)$1.3B+36.3% vs a year agoCapex $115M
Diluted EPS (TTM)$14.73+16.8% vs a year agoSum of the last 4 quarters
Net cash-$775M+14.3% vs a year agoCash + short-term investments - debt
  • Last report (2026-11-02): revenue beat by 1.9%, EPS beat by 6.2%Revenue $1.21B vs $1.19B expected (+1.9%); EPS $3.96 vs $3.73 (+6.2%).
  • Revenue growth slowing: 9.9% year on yearQ3 '26 revenue $1.21B, against an average of 12.9% over the four quarters before.
  • Operating margin 32.3% (TTM), +1.0 pp on a year agoOperating income grew 15.3% while revenue grew 11.9%.
  • Capex 2.5% of revenue (a year ago 3.2%)$115M invested in the last 4 quarters (-14.5% on a year earlier). Free cash flow $1.3B = 110.0% of net income.

Revenue, operating income and growth

quarterly

Revenue by business line

latest quarter
LineRevenuey/yShare
Product$723M+10.2%59.5%
Service$491M+9.4%40.5%
In the full financialsIncome statement, balance sheet and cash flow (12 quarters / 10 years) · margins and cost structure · capital allocation and buybacks · valuation against the 5-year range · analyst estimates · all 303 lines IDEXX Laboratories, Inc. reported to the SEC

Next catalyst

Catalysts

Earnings
2027-02-01
Revenue est. $1.2B · Updated 51m ago

No unusual perp activity right now.

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 202614.87$4.7B+10%9
FY 202716.82$5.2B+20%10
FY 202819.18$5.7B+31%9
FY 202921.87$6.2B+43%3
FY 203024.79$6.7B+57%3
Q2 20274.61$1.3B+9%2

Company events

6
2027-02-01EarningsActual - / Estimate 3.33-
2026-11-02EarningsActual 3.96 / Estimate 3.73Beat
2026-08-04EarningsActual 4.27 / Estimate 3.94Beat
2026-05-05EarningsActual 3.47 / Estimate 3.41Beat
2026-02-02EarningsActual 3.08 / Estimate 2.93Beat
2025-11-03EarningsActual 3.4 / Estimate 3.14Beat

Peer comparison

Similar listed perps

Company data

Company intelligence

Updated: Nov 5, 2026, 12:55 PM UTC

Company profile

Sector
Healthcare
Industry
Medical - Diagnostics & Research
Chief executive
Michael Erickson
Employees
11,000
IPO date
Jun 21, 1991
Country
US
Exchange
NASDAQ Global Select
Website
Altman Z-scorei23.42
Piotroski scorei9/9
Overall ratingiB
Owner earningsi$445.03M$5.63 per share
ESG risk ratingiB-Industry rank: 59 out of 62

Rating factors

Return on equityi
5
Return on assetsi
5
Debt to equityi
2
Price to earningsi
2
Price to booki
1
Market cap history
$55.06B+17.6%Aug 26 – Nov 26
$40.81B$47.94B$55.06BLow: $40.81B · 2026-09-14Latest: $55.06B · 2026-11-04Aug 26Sep 26Oct 26Nov 26
Latest: $55.06B · 2026-11-04High: $55.06B · 2026-11-04Low: $40.81B · 2026-09-14
Largest fund holders
FundWeightShares held
VTI0.06%2.5M
VOO0.06%2.1M
VO0.41%1.7M
QQQ0.24%1.7M
IVV0.08%1.1M
VUG0.13%1M
SPY0.08%970.3K
FXAIX0.06%760.6K
VOT0.97%618.5K
XLV0.79%583.3K
NIW1.45%528.8K
VIIIX0.06%416.5K

Analyst track record

How the analysts covering IDXX have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings54167
Analysts1416
Buy / hold / sell31 / 23 / 099 / 67 / 1
Upgrades / downgrades / initiations0 / 0 / 41 / 2 / 8
Price targets hit / missed14 / 31 (31%)101 / 51 (66%)
Avg. return after a rating (TipRanks)-4.6%+14.3%
Best / worst call+12.7% / -17.8%+66.3% / -17.8%

After buy calls on this stock: not enough measured cases yet

Latest ratings

DateAnalystCallTarget
Nov 3, 2026Jonathan BlockStifel NicolausBuyMaintained$700
Nov 3, 2026Keith DevasJefferiesBuyReiterated$770
Nov 3, 2026Erin WrightMorgan StanleyBuyReiterated$810
Nov 3, 2026Andrea AlfonsoUBSHoldReiterated$700
Oct 27, 2026Andrea AlfonsoUBSHoldReiterated$627

TipRanks data · computed Nov 5, 2026 · 54 ratings

Frequently asked questions

Where can I trade IDXX perpetual futures?

IDEXX Laboratories, Inc. (IDXX) perpetual futures trade on 1 crypto venues, including MEXC. PerpEquities compares them by live price, funding rate, open interest and liquidity.

Can I trade IDXX around the clock?

Yes. Unlike the underlying stock, IDXX perpetuals trade 24/7 — including weekends and outside regular market hours.

What is the funding rate on IDXX perpetuals?

Right now the IDXX perp funding rate is +15.4% annualized (venue median), ranging from +15.4% to +15.4% across 1 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.

How does the IDXX perp price compare to the IDEXX Laboratories, Inc. stock?

The venue-median IDXX perp mark is $708.7 versus a reference stock price of $708.7, a basis of 0.0%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.

What is a IDXX perpetual future?

A IDXX perpetual is a derivative that tracks the price of IDEXX Laboratories, Inc. with no expiry date. It lets you take long or short exposure to IDEXX Laboratories, Inc. on crypto venues, around the clock.

What is IDXXUSDT perpetual?

IDXXUSDT is the symbol most crypto exchanges use for the IDEXX Laboratories, Inc. perpetual settled in USDT (Tether). It tracks the IDXX share price through an index, trades 24/7 with leverage and never expires.

Embed this asset

IDXX perpetuals · perpequities.comIDXX perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/idxx-perp"><img src="https://perpequities.com/badge/idxx-perp.svg" width="240" height="64" alt="IDXX perpetuals · perpequities.com" loading="lazy"></a>

Next step

Stay on top of IDXX perps

Signals with a track record

Analysts who hit 70%+ of their targets on the perps we track, congress buys over $500k, 13F positions over $5M, funding spreads that have paid for days. Every post shows the evidence. Free, no sign-up.

Join on Telegram

Weekly digest by email

The listings, funding and moves that matter for IDXX — one email every Sunday.

Watchlist and alerts

Price and funding alerts for IDXX, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X